Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.67 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 3/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 7/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12129519 | 0.89 | APP (0.61) | APPSYKEGFRAHRMAOA | |
| SCHEMBL30302572 | 0.83 | APP (0.49) | APPSYKEGFRRETESR1 | |
| SCHEMBL22803665 | 0.83 | APP (0.49) | APPSYKEGFRRETESR1 | |
| SCHEMBL22803849 | 0.82 | APP (0.48) | APPSYKEGFRRETAHR | |
| SCHEMBL22803799 | 0.82 | APP (0.48) | APPSYKEGFRRETAHR | |
| SCHEMBL22803666 | 0.82 | SYK (0.52) | APPSYKEGFRRETAHR | |
| SCHEMBL30302513 | 0.82 | APP (0.48) | APPSYKEGFRRETAHR | |
| SCHEMBL12129007 | 0.82 | SYK (0.55) | SYKEGFRRETAHRCMA1 | |
| SCHEMBL25120719 | 0.81 | APP (0.50) | APPSYKEGFRRETAHR | |
| SCHEMBL12128973 | 0.81 | APP (0.52) | APPSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558446-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2019-06-12 | — | — | EP | disclosed |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE SA (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE SA (CH) | 2016-06-09 | — | — | US | disclosed |
| US-9221812-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2015-12-29 | — | — | US | disclosed |
| US-9221812-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2015-12-29 | — | — | US | disclosed |
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE, S.A. (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE, S.A. (CH) | 2011-11-17 | — | — | US | disclosed |
| WO-2011128455-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE S.A. (CH) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | APP, PSEN1, PSEN2 | APP 1/4885SYK 3892/4885EGFR 3704/4885 |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | APP, PSEN1, PSEN2 | APP 1/4885SYK 3892/4885EGFR 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.